2023-503785-22-00
CTIS ↗
SPR994-305
complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)
pharma · Renal Impairment · Urinary Tract Infection · SPRO
Spero Therapeutics
Spero Therapeutics trial registry — 24 ClinicalTrials.gov studies with program phase, status, and indication context.
675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US HQ
2013 Founded
45 Employees
Public company Type
SPRO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US
- Founded
- 2013
- Employees
- 45
- Programs
- 21
- Drugs
- 9
- Patents
- 16
Spero Therapeutics clinical trials
Registry index of 24 ClinicalTrials.gov studies linked to Spero Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Spero Therapeutics trial registry — 24 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Spero Therapeutics.
-
SPR994-305 — Phase 3
Clinical update -
Tebipenem tablet form — Phase 1
Clinical update -
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) — Phase 1
Clinical update -
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference — Phase 1
Clinical update -
Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo — Phase 1
Clinical update -
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) — Phase 1
Clinical update -
Tebipenem Pivoxil Hydrobromide — Phase 1
Clinical update -
Placebo — Phase 2
Clinical update